Hutchison China MediTech has started a phase II study of savolitinib in locally advanced or metastatic pulmonary sarcomatoid carcinoma in China.
Savolitinib is a highly selective and potent oral c-Met inhibitor with global first-in-class potential.
The first drug dose was administered on 10 February. This phase II study is a multi-centre, single-arm, open-label study to evaluate the efficacy and safety of savolitinib as a monotherapy in treating locally advanced or metastatic PSC patients harboring mesenchymal epithelial transition gene alterations.
The primary endpoint is objective response rate (ORR), with secondary endpoints including progression free survival (PFS), disease control rate (DCR), duration of response (DoR), overall survival (OS) and safety.
Additional details about this study can be found at clinicaltrials.gov, using identifier NCT02897479.
At 9:06am: (LON:HCM) Hutchison China Meditech Ltd share price was 0p at 2165p
Story provided by StockMarketWire.com